Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b ...

Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic mutations and imatinib failure, and dasatinib with a switch to imatinib.

With recent advances, treatment for chronic myeloid leukemia (CML) can often slow or stop the progression of the disease. Today, CML may be treated similarly to a chronic long-term condition. The goal ...

Nilotinib (Tasigna®) is a highly potent and selective inhibitor of breakpoint cluster region (BCR)–V-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1), which was rationally designed based on ...

Chronic myeloid leukemia (CML) is a type of cancer that causes blood cells to grow out of control. If you’ve been diagnosed with CML, it’s important to get treatment from healthcare professionals who ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced ...

Shares of Enliven Therapeutics (NASDAQ:ELVN) climbed 7% on Thursday after the company released positive early results from a ...

Chronic myeloid leukemia (CML) is a type of blood cancer that people may also refer to as chronic myelogenous leukemia. Doctors diagnose the stage of CML based on the number of leukemia cells, or ...

With today’s medicines, most people with chronic myeloid leukemia (CML) have a normal lifespan and a good quality of life. The key is to get care from CML experts — like the physicians at Fred ...

Terns Pharmaceuticals climbed by 629.64 percent in 2025, primarily boosted by stellar results from the clinical trial of its ...